argenx SE (ARGX)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

€840.00

Buy

€855.00

arrow-up€38.00 (+4.66%)

Prices updated at 09 Nov 2026, 16:39 CET

Prices minimum 15 mins delay

Prices in EUR

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company’s lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myas ...

FTSE EuroFirst 300

1.3%

Brussels

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

our Investment Fees and Charges.

	€856.60 - €824.20
	€925.00 - €568.40
	-
	51,302.46m
	31.75
	-
	108,220
	6.85
	89,874.86
	-0.19
	61.88m
	NL0010832176
	19.57
	-

Please note that past performance is not a reliable indicator of future returns. Pre-sale Illustration.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser.

© Copyright 2026 Morningstar. All rights reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

The ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.